



2020 Tracleer® Prior Authorization Request

Page 1 of 3

(You must complete all pages.)

Fax completed form to: 1-800-408-2386

For urgent requests, please call: 1-800-414-2386

Coverage criteria:

- Medication is covered on plan when being prescribed for:
 - Pulmonary arterial hypertension (PAH) (WHO Group 1) in adults to improve exercise ability and decrease worsening, when PAH is confirmed by right heart catheterization **OR** pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability when PAH has been confirmed by right heart catheterization

AND

For NEW starts, the patient must have ALL the following:

1. Pretreatment mean pulmonary arterial pressure is greater than or equal to 25 mmHg
2. Pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg
3. Pretreatment pulmonary vascular resistance is greater than 3 Wood units

Authorization duration: Through end of plan contract year

Patient information		Prescriber information	
Patient name		Today's date	Physician specialty
Patient insurance ID number		Physician name	NPI/DEA number
Patient address, city, state, ZIP		Physician address, city, state, ZIP	
Patient home telephone number		M.D. office telephone number	
Gender <input type="checkbox"/> Male <input type="checkbox"/> Female	Patient date of birth	M.D. office fax number	
Diagnosis and medical information			
Medication requested		Frequency	
<input type="checkbox"/> Tracleer 32 mg tablet for oral suspension <input type="checkbox"/> Tracleer 62.5 mg tablet <input type="checkbox"/> Tracleer 125 mg tablet			
New prescription OR date therapy initiated		Quantity	Day supply
			Expected length of therapy
Diagnosis (Please check all boxes that apply and include all office notes supporting diagnosis.) <input type="checkbox"/> Treatment of pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group I, in adults to improve exercise ability and decrease worsening <input type="checkbox"/> Treatment of pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group I in pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension to improve pulmonary vascular resistance, which is expected to result in an improvement in exercise ability <input type="checkbox"/> Other diagnosis/ (ICD 10): _____			

(continued on page 2)

Fax Confidentiality Notice: The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). The message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to criminal or civil penalties. **If you received this transmission in error, please notify us immediately by telephone at 1-800-414-2386.**

Please check all boxes that apply:

1. Patient is stable on current drug(s) and/or current quantity, and therapy change would likely result in adverse clinical outcomes.
2. All covered Part D drugs on any tier of the plan's formulary would not be as effective for the enrollee as the requested formulary drug and/or would likely have adverse effects for the enrollee.

3. For the diagnosis of WHO Group I pulmonary arterial hypertension (PAH): Please complete this section.

Yes No Was the diagnosis of pulmonary arterial hypertension (WHO Group I) confirmed by right heart catheterization?

For NEW STARTS only:

Yes No Was the pretreatment mean pulmonary arterial pressure greater than or equal to 25 mmHg?

Yes No Was the pretreatment pulmonary capillary wedge pressure less than or equal to 15 mmHg?

Yes No Was the pretreatment pulmonary vascular resistance greater than 3 Wood units?

Please complete this section below only if your patient does not meet the standard requirements listed above.

Please explain why your patient should be considered for exception although not meeting the plan's suggested PA criteria. Statement should include specifically which requirement is not met and why patient should be exempt from meeting this requirement. (Please note any information that is incomplete or illegible will delay the review process.)

4. Yes No **Tracleer 32mg tablet for oral suspension and Tracleer 62.5mg have quantity limits (QL) of 120 tablets per 30 days. Tracleer 125mg tablet has a quantity limit (QL) of 60 tablets per 30 days. Does the patient require higher dosage (quantity limit exception)?**

▶ If yes, indicate quantity requested: _____ per 30 days OR quantity _____ per day

The number of doses available under the dose restriction for the prescription drug has been ineffective in the treatment of the enrollee's disease or medical condition.

The number of doses available under the dose restriction for the prescription drug, based on both sound clinical evidence and medical and scientific evidence, the known relevant physical or mental characteristics of the enrollee, and known characteristics of the drug regimen, is likely to be ineffective or adversely affect the drug's effectiveness or patient compliance.

5. Please list all medications the patient has tried specific to the diagnosis and specify below.

CURRENT/PAST MEDICATIONS USED	DATES OF TREATMENT	THERAPEUTIC OUTCOME

(continued on page 3)

Please check all boxes that apply (continued):

6. **Other supporting information**

*NOTE: All exception requests require prescriber supporting statements. Additionally, requests that are subject to prior authorization (or any other utilization management requirement), may require supporting information. Please attach supporting information, as necessary, for your request.

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that documentation supporting this information is available for review if requested by the health plan sponsor, or, if applicable, a state or federal regulatory agency. I understand that any person who knowingly makes or causes to be made a false record or statement that is material to a claim ultimately paid by the United States government or any state government may be subject to civil penalties and treble damages under both the federal and state False Claims Acts. See, e.g., 31 U.S.C. §§ 3729-3733. By signing this form, I represent that I have obtained patient consent as required under applicable state and federal law, including but not limited to the Health Information Portability and Accountability Act (HIPAA) and state re-disclosure laws related to HIV/AIDS.

Prescriber signature

Date

Fax Confidentiality Notice: The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). The message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to criminal or civil penalties. **If you received this transmission in error, please notify us immediately by telephone at 1-800-414-2386.**